stockrowBaxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.
- Revenue
- +4.97%
- EPS
- +731.9%
- Free cash flow
- +255.6%
- Total debt
- −9.48%
Quarter to September 2026, against a year earlier
Follow BAX
Alert me
Baxter International Inc. (BAX) Return on assets
Baxter International Inc.'s return on assets over the twelve months to 30 September 2026 was −3.57%, up 0.6 percentage points from fiscal 2025 (−4.18%). Over the past ten years it has ranged from −7.87% (fiscal 2022) to 27.2% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −4.18% | (1.78) |
| FY2024 | −2.40% | (11.79) |
| FY2023 | 9.39% | 17.26 |
| FY2022 | −7.87% | (12.67) |
| FY2021 | 4.80% | (0.97) |
| FY2020 | 5.77% | (0.13) |
| FY2019 | 5.90% | (3.52) |
| FY2018 | 9.42% | 5.73 |
| FY2017 | 3.69% | (23.51) |
| FY2016 | 27.2% | 23.09 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | 15.7% |
| ALGN Align Technology, Inc. compare | 7.71% |
| ATR AptarGroup, Inc. compare | 5.23% |
| COO The Cooper Companies, Inc. compare | 4.55% |
| AVTR Avantor, Inc. compare | 2.89% |
| SOLV Solventum Corporation compare | 1.11% |
| RGEN Repligen Corporation compare | −0.40% |
| BLCO Bausch + Lomb Corporation compare | −0.80% |
| BAX Baxter International Inc. | −3.57% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BAX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement